FinscoFinsco

Eton Pharmaceutical (US.ETON)

Capital Allocation Audit · Period: 2018 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ETON · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion-103.6%↓
ROE5.1%↑
Cash Conversion476.5%→
D/E Ratio1.02↑
Gross Margin60.7%↑
US.ETON (Eton Pharmaceutical) | YoY: 2026 Q1 vs 2025 Q1


Metric             Value  YoY
-----------------------------
FCF Conversion   -103.6%    ↓
ROE                 5.1%    ↑
Cash Conversion   476.5%    →
D/E Ratio           1.02    ↑
Gross Margin       60.7%    ↑
Key Metrics
US.ETON (Eton Pharmaceutical) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
-----------------------------
FCF Conversion -103.6% ↓
ROE 5.1% ↑
Cash Conversion 476.5% →
D/E Ratio 1.02 ↑
Gross Margin 60.7% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies